Abstract
The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). An international registry named Pharmachild (European Union grant 260353) has been set up by the Pediatric Rheumatology International Trials Organisation (PRINTO)/Pediatric Rheumatology European Society (PRES). In parallel several national registries with the same purpose have been set up in different European Countries for the follow-up of these patients.
Highlights
The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA)
Data are presented as frequencies (%) or medians with 1st and 3rd quartiles
About 63% of the patients has been treated with biologicals alone or in combination with MTX, and 29% only with MTX
Summary
The availability of methotrexate (MTX) and biological agents has provided a major change in the treatment of children with juvenile idiopathic arthritis (JIA). Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries Joost Swart1*, Alessandro Consolaro2, Gerd Horneff3, BIKER, Kimme L Hyrich4, UK BCRD Study Group and BSPAR Etanercept Study Group, Francesca Bovis2, Jose Melo-Gomes2, Ekaterina Alexeeva2, Stefano Lanni2, Gerd Ganser5, Violeta Panaviene2, Jordi Anton2, Ivan Foeldvari6, Valda Stanevicha2, Susan Nielsen2, Ralf Trauzeddel7, Constantin Ailioaie2, Pierre Quartier2, Toni Hospach8, Gordana Susic2, Maria Trachana2, Frank Weller-Heinemann9, Alberto Martini2, Nico Wulffraat2, Nicolino Ruperto2
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
